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Abstract
Objective: To examine factors that predict glycemic control in children and adolescents with
Type 1 diabetes in Southwestern Ontario from 1998-2008.
Methodology: A population based cohort study was conducted using local pediatric clinical
diabetes database (Humabase) to determine demographic and diabetes-related clinical factors
that predict achievement of the target glycemic control under 'real world' conditions. Clinical
parameters including the outcome (A1C level) were documented in Humabase. Socioeconomic variables were derived using Forward Sortation Area and linking it to the Census
of Canada Data.
Results: Factors associated with improved glycemic control were age-specific. Longer
distance from the treatment center (OR 0.35), female gender (OR 0.45), longer diabetes
duration (OR 1.12), and greater body mass index at diagnosis (OR 1.07) predicted
achievement of the target glycemic control on multivariable analyses.
Conclusions: In this regional cohort we identified factors that predict glycemic control.
Targeted support should be considered for high risk individuals.

Keywords
Type 1 diabetes; children and adolescents; pediatric; population-based; electronic databases;
predictors; glycemic control; A1C
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Chapter 1

1 Introduction
Type 1 diabetes (T1D) is a common chronic disorder of childhood that is characterized by
insulin deficiency resulting in chronic hyperglycemia. Chronically elevated blood glucose levels
lead to multiple long term diabetes complications involving the eyes, kidneys, nerves, and heart
and blood vessels. The incidence of T1D is increasing worldwide by 3-5% per year (Maahs,
West, Lawrence, & Mayer-Davis, 2010). Despite new treatments and improvement in the
survival rates over the past 30 years, those who are diagnosed with T1D in childhood still have
up to a 6 fold increase in mortality compared to the general population (Secrest, Becker, Kelsey,
LaPorte, & Orchard, 2010).
The complexity and intensity of T1D management in childhood continues to increase. The goal
of diabetes management is to provide care that will result in lowest possible risk of diabetes
complications. Intensification of insulin treatment and achievement of tight glycemic control in
adolescent and adults with T1D prevents the onset and progression of long term complications
such as blindness, dialysis, limb amputations, strokes and heart attacks (Diabetes Control and
Complications Trial [DCCT] Research Group, 1993). In addition, optimal glycemic control is
best achieved through an access to interdisciplinary pediatric diabetes health care team. The
interdisciplinary treatment approach is a key intervention that has been shown to improve health
outcomes (Glasgow et al., 1991) and is the current standard of pediatric diabetes care in Canada.
Treatment goals and strategies should also give consideration to complex physiologic,
developmental, and social needs of children and adolescence to ensure the best long-term
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outcomes (Canadian Diabetes Association [CDA] Clinical Practice Guidelines, 2008). Diabetes
management in childhood is clearly complex and there is more than one approach toward
improving the metabolic control in children and adolescents with T1D.
Optimal glycemic control in children and adolescents is essential. However, optimal glycemic
control is difficult to achieve in the ‘real-world’. Observational population-based studies have
indicated suboptimal levels of glycemic control worldwide despite the well-publicized results of
the DCCT (Petitti et al., 2009; Johannesen et al, 2008; Hanberger et al, 2008; Gerstl et al, 2007).
Surveillance and quality assurance programs on childhood diabetes provided helpful data on
glycemic outcomes but there is a limited literature on factors responsible for the suboptimal
glycemic levels in the ‘real-world’. In Canada, there are no studies that have examined predictive
variables and their influence on the glycemic outcomes in the unselected population of children
and adolescents. Therefore, improving understanding of optimal glycemic control in children and
adolescents with T1D treated under ‘real-world’ conditions would be useful. In this thesis, we
have explored an opportunity to assess selected predictors of optimal glycemic control under
real-life, ‘effectiveness’ conditions through the use of a unique electronic clinical database in
Southwestern Ontario.
Previous research has identified a number of socio-demographic and clinical factors associated
with better glycemic control. Factors such as gender, age, ethnicity, family structure and
socioeconomic status, duration of diabetes and treatment approach have been found to be
associated with glycemic control in cross sectional studies (Dorchy, Roggemans, &Willems,
1997; Rosilio et al., 1998; Mortensen & Hougaard, 1997). However, there are only a few
prospective studies that have assessed the predictors of long term glycemic control (Shalitin &
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Phillip, 2011; Cutfiled et al., 2011; Johannesen et al., 2008; Hanberger et al., 2008; Gerstl et al.,
2007; Palta et al., 1996). Determining the factors that predict achievement of glycemic control in
children and adolescents with T1D is important since it allows for identification of high risk
groups, promotion of early intervention, and appropriate resource allocation for this particularly
vulnerable patient group.
Our research goal was to assess predictors of glycemic control in children and adolescents with
T1D using data from a large regional clinical electronic database in Ontario. This was a unique
opportunity to study determinants of glycemic control in a geographically defined region. All
children newly diagnosed with T1D in the Southwestern Ontario, a region of 2.5 million people,
are referred to Children’s Hospital, London Health Sciences Centre (CH-LHSC) specialized
pediatric diabetes program. Therefore, our study population was highly representative of the
region. Moreover, as there are no studies looking at the predictors of glycemic control in Canada,
this study was the first to address this issue.
This study is the first step of program research aimed at creating a research database and
conducting exploratory analyses using pediatric clinical electronic data.
Our research was set in the context of the increasing use of electronic medical records (EMR)
and databases in diabetes research. We used, for the first time, a local pediatric clinical diabetes
database (Humabase) that has maintained demographic and clinical information on
approximately 2000 pediatric T1D patients in the Southwestern Ontario since the late 1980’s.
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1.1 Thesis Objectives
The purpose of this study was to determine factors that are associated with glycemic control (as
measured by the glycated hemoglobin or A1C level) in children and adolescents with T1D to
answer the following research question:
Are there demographic and diabetes-related clinical factors that predict
achievement of future target glycemic control in children and adolescents with T1D
in Southwestern Ontario?
The three main objectives directly related to the primary research question were as follows:
Objective 1: To establish a pediatric diabetes cohort in Southwestern Ontario from 1998-2008
using a regional electronic clinical database for future studies in Type 1 diabetes
Objective 2: To describe and examine social, demographic, and clinical characteristics of this
cohort.
Objective 3: To identify factors predictive of glycemic control in the following three age groups:
< 6 years of age, 6-12 years, and > 12 years of age.
.
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Chapter 2

2 Type 1 Diabetes in Children and Adolescents
Chapter 2 is divided into seven sections and provides an overview relevant to this research. The
initial part of the chapter will provide background information on T1D including the burden of
this disease, epidemiology and pathogenesis of T1D, and a brief description of diabetes-related
complications. It also summarizes the evidence on management including goals of glycemic
control in children and adolescents with T1D. Next is a section presenting background literature
on the factors predicting achievement of glycemic control in this population. The last section will
integrate the findings and incorporate them into a discussion on quality and current standard of
pediatric diabetes care.

2.1 Incidence of Type 1 Diabetes
T1D is one of the most common chronic illnesses of childhood, second only to asthma (Osgood,
Foster, & Courtney, 2010). Globally, the incidence of T1D varies with the lowest rates in
developing countries (e.g. China and Venezuela) and the highest rates in developed countries
such as Finland. Importantly, the incidence rates of childhood T1D are increasing worldwide.
The average annual incidence increase is 3% with the steepest increase in the youngest age
groups and lower incidence areas (International Diabetes Federation [IDF], 2011). If the current
trends continue, the incidence of T1D will double every 20 years (Daneman, 2009). Canada has
the sixth highest incidence of T1D in children 14 years or younger in the world (IDF, 2007). The
incidence of T1D is rising by three to five percent per year in Canada; the greatest increase has
occurred in children aged 5 to 9 years. In Ontario, the Institute for Clinical Evaluative Science
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(ICES) has reported an overall 17% increase in incidence of diabetes in children between 1996
and 2000. The incidence of diabetes among Ontario children under 19 years of age was
28/100,000 in 2000 (To, Curtis, & Daneman, 2003). Currently, over 240,000 Canadians live with
T1D (Juvenile Diabetes Research Foundation of Canada [JDRF], 2012).
It is particularly concerning that the incidence of T1D is increasing in the youngest age group.
Given that children who develop diabetes early are more at risk to develop long-term
complications, these data underline the immense personal and societal impact of T1D in the
pediatric population.

2.2 Pathogenesis of Type 1 Diabetes
Type 1 Diabetes (T1D) is an autoimmune disorder characterized by destruction of the insulin
producing pancreatic beta cells in genetically susceptible individuals. The etiology of T1D
remains unknown. While major susceptibility genetic loci for T1D have been identified, only a
small percentage (<5%) of individuals with genetic susceptibility develop clinical disease
(Mehers & Gillespie, 2008; Virtanen & Knip, 2003). This is explained by a powerful influence
of one or more environmental triggers (TEDDY Study Group, 2008). Putative triggers include
infectious agents (eg, enteroviruses, coxsackie, congenital rubella) or components of early diet
(cow milk protein, cereal or gluten exposure) (TEDDY study group, 2008; Maahs et al., 2010).
Clinical diabetes develops when the continuing destruction of pancreatic beta cells finally results
in absolute insulin deficiency (Daneman, 2006). This process results in lifelong dependency on
daily insulin injections for survival.
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2.2.1 Phases of Diabetes in Children and Adolescents
Type 1 diabetes in the pediatric population is characterized by a preclinical phase, presentation,
partial remission or honey moon phase and finally a chronic lifelong insulin dependent phase
(International Society for Pediatric and Adolescent Diabetes [ISPAD] Clinical Practice
Guidelines, 2009). Preclinical diabetes is the phase before presentation, during which markers of
autoimmunity may be identified. In contrast to type 2 diabetes which can often go undiagnosed
for months and years, the clinical onset of T1D usually follows an acute and dramatic course.
The presentation of T1D is often complicated by diabetic ketoacidosis (DKA), a life threatening
event. In Manitoba, the frequency of DKA at presentation of T1D in children age <18 years
ranged from 21.8%-35.1% (2010 Winnipeg Child Health Program Annual Report, n.d.), whereas
a European EURODIAB study reported DKA in 42% of children (Levy-Marchal et al., 2001).
The honeymoon or partial remission period occurs soon after clinical diagnosis and initiation of
insulin therapy. In 42-80 % percent of children and adolescents, insulin requirements decrease
transiently following initiation of insulin treatment (Lombardo et al., 2002; Kordonouri et al.,
2008). It is suspected that remaining beta cells that are exhausted but not yet destroyed restore
endogenous insulin production at the same time as insulin resistance decreases with the
alleviation of hyperglycemia (Daneman, 2006; Aly & Gottlieb, 2009). The partial remission
phase commences within days or weeks of the start of insulin therapy and may last for weeks to
months. Lombardo and colleagues report that the mean duration of the partial remission period is
11.7 +/- 8.9 months. In a few children and adolescents, requirements for insulin may decrease to
the point of being able to withdraw insulin therapy temporarily and still maintain
normoglycaemia (Hanas, Donaghue, Klingensmith, & Swift, 2006, 2009). This partial remission
phase is always transient and progresses to the chronic phase of lifelong insulin dependence.
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2.3 Diabetes Complications
Long term diabetes complications are divided into microvascular and macrovascular
complications. Microvascular complications include nephropathy, retinopathy, and neuropathy,
while cardiovascular, cerebrovasular and peripheral vascular disease are the components of
macrovascular complications.

2.3.1 Nephropathy
A declining incidence of reported complications in many areas with specialized diabetes clinics
has been noted (Mohsin et al., 2005). Still, diabetic nephropathy is a major cause of morbidity
and mortality among young adults with T1D (Schultzs et al., 1999).The cumulative prevalence of
microalbuminuria (a marker of future renal failure) in childhood onset T1D is between 12-25%
after 5-10 years of disease (Amin et al., 2008). Microalbuminuria has been shown to be highly
predictive of progression to advanced stages of diabetic nephropathy. However, the rate of this
progression has varied across studies with a range between 50-80% (Mogensen, 1982; Viberti,
Jarrett, & Keen, 1982; Perkins et al., 2003). More recent studies have shown a decline in the rate
of progression to advanced nephropathy. In a cohort of 20,005 individuals from Finland
diagnosed younger than 30 years of age between 1965 and 1999, Finne, Reunanen, Stenman,
Groop, & Gronhagen-Riska (2005) reported a cumulative prevalence of end-stage renal disease
of 2.2% at 20 years.

2.3.2 Retinopathy and Neuropathy
Diabetic retinopathy is the most common cause of acquired blindness in the Western world, with
a prevalence rate of proliferative retinopathy of about 20–25% in T1D (Fong, Aiello, & Ferris,
2004). Retinopathy and neuropathy are unlikely to develop before age 15 years and less than 5
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years of diabetes duration (Olsen et al., 2000). A close relationship between diabetic retinopathy
and nephropathy exists (Klein, Klein, Linton, & Moss, 1992, 2005). Routine screening for
microvascular complications is generally initiated at 12-15 years of age in children 5 years after
the onset of T1D. Diabetic neuropathy is rarely reported in children, however screening is
recommended at the same age as for the other microvascular complications.

2.3.3 Macrovascular Complications
Children with T1D have up to a 10-fold higher risk of macrovascular complications in adulthood
compared to the population with no diabetes (Daneman, 2006). Risk factors for cardiovascular
disease in childhood include the presence of microvascular complications, dyslipidemia,
hypertension, obesity, smoking, and a family history of premature cardiovascular disease
(Daneman, 2006; Egg-Olefsson et al., 2007; Palta et al., 2009). Presence of childhood
cardiovascular risk factors have been unequivocally shown to be associated with accelerated
atherosclerosis (Katzmarzyk et al., 2004; McGill et al., 2002). The increasing prevalence of
obesity globally has also affected children with T1D and has led to a rise in associated risk
factors for macrovascular disease (Krishnan & Short, 2009). Van Vliet and colleagues (2010)
have shown in a Dutch cohort of 283 children age 3-18 years with a mean duration of diabetes of
5.3 years, that 38.5% were overweight or obese. Hypertension was found in 13.1% of patients,
and elevated LDL cholesterol in 17.3%. In a Norwegian study on prevalence of cardiovascular
risk factors in children with T1D, obesity was less prevalent (4%) but 86% of children had at
least one cardiovascular risk factor (Margeirsdottir, Larsen, Kummernes, Brunborg, & DahlJorgensen, 2008). The presence of two cardiovascular risk factors was reported in 14% of
children with T1D in the SEARCH for diabetes in youth study (Rodriguez et al., 2006).
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In Canada, the prevalence of overweight and obese children with T1D in Manitoba was 24.7%
with the highest rate in females age 12-18 years old (38.2%) (2010 Winnipeg Child Health
Program Annual Report, n.d.). Early detection and management of cardiovascular risk in
children and young adults with T1D is important. For example, the Epidemiology of Diabetes
Interventions and Complications study (EDIC), a long term follow up study of the DCCT,
showed that intensive insulin treatment decreased macrovascular complications in T1D patients
over the long-term (Nathan et al., 2005).

2.4

Management of Type 1 Diabetes in Children and
Adolescents

2.4.1 Rational and Goals
The primary goal of T1D treatment in children is avoidance of acute and prevention of long term
diabetes complications. Hypoglycemia and diabetic ketoacidosis (DKA) are serious, potentially
life threatening acute complications. They are the major cause of mortality and morbidity in
younger patients with T1D. Sixty-eight percent of diabetes related deaths in children and young
adults with established T1D are due to hypoglycemia or DKA (Laing et al., 1999). Chronic
complications, such as nephropathy, neuropathy, or retinopathy are less frequent in pediatric
population. However, once developed chronic complications are a major contributor to diabetes
morbidity and mortality (Mathiesen, Hommel, Hansen, Smidt, & Parving, 1999) and therefore
prevention is a major focus of diabetes management in adolescents and younger patients with
longer duration of diabetes.
Optimal blood glucose control is essential to the prevention of diabetes complications and is the
major focus of T1D management.
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2.4.2 Glycemic Targets
Glycated hemoglobin (A1C) is a test that reflects mean blood glucose levels over the proceeding
3-4 months. It is a reliable measure of treatment effectiveness and is used to set the target values
for glucose control (American Diabetes Association [ADA], 2011). These targets are largely
based on evidence that showed that optimal glycemic control determined by A1C levels
decreases the risk for diabetes complications.
The Diabetes Control and Complications Trail, the largest randomized control trial of different
glycemic targets in subjects with T1D, demonstrated that strict blood glucose control (mean A1C
7.2%) was associated with 30-70 % reduced risk of retinopathy, neuropathy, nephropathy, and
serious cardiovascular outcomes (Nathan et al., 2005). Intensive insulin treatment, defined as
three or more insulin injections a day or continuous subcutaneous insulin injection (an insulin
pump), was used in the treatment group to achieve glycemic targets. The DCCT also showed that
there was no threshold effect as any decrease in A1C concentrations is associated with a decline
in the relative risk for complications. Furthermore, there is no A1C level below which
complications are not completely prevented, nor one above which complications are certain to
develop (Daneman, 2006). This landmark trial included 195 T1D subjects age 13-18 years. As a
result of this study, there is strong evidence that target A1C levels in adults and in children age
13-18 years should be <7%. There is no similar level of evidence to assess A1C targets for
children younger than age 13 years.
Current CDA Practice Guidelines recommend the following glycemic targets (Table 1): A1C
<8.5% for children 0–6 years of age, <8% for those 6–12 years of age, and ≤ 7% for 13-18 years
of age (CDA Clinical Practice Guidelines Expert Committee, 2008). These recommendations are
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based on the consensus of the Steering and Executive Committees of the CDA. Rigorously
conducted studies in young children with T1D determining optimal A1C values are limited. The
main limiting factors are the low incidence of chronic complications in the youngest age groups
and the particularly high risk of hypoglycemia. For example, in the DCCT adolescent cohort
there was a 2-4 fold increase in the risk of hypoglycemia in the intensive versus control group
(DCCT Research Group, 1993). The onset of diabetes at age < 7 years of age has been associated
with recurrent hypoglycemic episodes and poor cognitive function (Ryan, Gurtunca, & Becker,
2005). Therefore, treatment goals in young (age <13 years) T1D patients should be
individualized and aim to achieve a target A1C without recurrent hypoglycemia (CDA Clinical
Practice Guidelines, 2008). Challenges in determining the A1C target goals in pediatric
populations are reflected in the different recommended target values across different diabetes
organizations that publish guidelines across the world (see Section 2.5 Determinants of glycemic
control).
In summary, there is a pivotal role of glycemic control in the management of childhood T1D.
The glycemic goals of diabetes management in children and adolescents with T1D are based on
the prevention of acute and/or chronic diabetes complications with age-specific targets also being
directed by the risk for hypoglycemia.
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Table 1: Recommended Glycemic Targets for children with T1D
(2008 Canadian Diabetes Association Practice Guidelines)
Age (years)

A1C (%)*

<6

< 8.5

6-12

< 8.0

13-18

< 7.0

*A1C – glycated hemoglobin

2.4.3 Distribution of Glycemic Control
The level of glycemic control in children with T1D varies worldwide. A mean A1C of 8.6% was
described in an international study of 2,837 children and adolescents including 22 centers in
Europe and Asia (Mortensen et al., 1997). The American-based SEARCH for diabetes in youth
study showed similar results with a mean A1C of 8.18% (Pettiti et al., 2009), while the largest
study of pediatric T1D patients from Germany and Austria (26,687 children with T1D in 152
pediatric centers) showed a mean A1C value of 7.6% (Gerstl et al., 2007). In the SEARCH
study, the percentages of children with A1Cs at target according to age were similar across age
groups: 44.8% (age<6), 43.6% (age 6-12), and 45.7% (age 13-18) (Pettiti et al., 2009). There are
fewer studies describing overall level of control in children and adolescents in Canada. In
Manitoba, the average A1C levels among children 0-10 years was 8.3%, while for children 11-18
years old the mean value was 8.9% (2010 Winnipeg Child Health Program Annual Report, n.d.).
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In this study, only 29.7 % of children age < 9 years were at a target A1C level while in two other
categories, age 10-14 and > 14 years, there were, respectively, 32.6% and 28.5 % children with
mean A1Cs at target (target A1C < 8.3% for 10-14 years and < 7% for > 14 years old).

2.5 Determinants of Glycemic Control
There is a significant body of literature describing factors associated with glycemic control in
children and adolescents with T1D. Information about potential determinants of glycemic control
was initially derived from cross-sectional studies (conducted 15-20 years ago) that explored
demographic or diabetes-related characteristics out of a number of candidate predictors that
independently contributed to the improved glycemic control. The evidence indicated that
children diagnosed at a younger age, who had longer diabetes duration, lived with one parent and
belonged to low income families, who checked their blood glucose less frequently and who had a
higher body weight were less likely achieve the target A1C values (Palta et al., 1996; Dorchy et
al., 1997; Mortensen et al., 1998; Rosilio et al., 1998; Danne et al., 2001; Craig, Jones, Silink, &
Ping, 2007).
Following is a brief summary of determinants of glycemic control in children and adolescents
with T1D considered in this thesis. These factors are further described in the next chapter (see
Section 3.3).
Gender
Female gender was correlated with worse glycemic control in previous studies (Petitti et al.,
2009; Danne et al., 2001; Gerstl et al., 2007). However, small studies that included a greater
proportion of prepubertal subjects have not reported gender differences in the glycemic control
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(Palta et al., 1996; Urbach et al., 2004, Shalitin & Philip, 2011). Earlier onset of puberty in
females, differential effect of sex hormones on insulin resistance, and higher prevalence of eating
disorders in adolescent females are suspected to be responsible for the effect of gender on
glycemic control (Jones, Lawson, Daneman, Olmsted, & Rodin, 2000; Amiel, Sherwin,
Simonson, Lauritano, & Tamborlane, 1986).
Age and Diabetes Duration
According to the literature glycemic control worsened as age increased (Rosilio et al., 1998;
Danne et al., 2001; Urbach et al., 2004; Petitti et al., 2009). There are multiple factors
responsible for this complex relationship such as progressive loss of beta cell function in the
early years of diagnosis, potential weight gain as a result of insulin treatment, insulin resistance
that develops at adolescence and a myriad of psychosocial factors such as decreasing compliance
with treatment and diet reported during teenage years (Gordon & Mansfield, 1996; Urbach et al.,
2004; Scholin et al., 2004). Similarly, several studies have demonstrated a pattern of worsening
glycemic control with increasing diabetes duration (Rosilio et al., 1998; Danne et al., 2001;
Petitti et al., 2009).
Distance from the Treatment Center
Location of a specialized diabetes treatment center correlated with glycemic control in a French
study (Rosilio et al., 1998). In describing their experience, Rosilio (1998) and colleagues
demonstrated better glycemic control in the participants who lived closer to the treatment center
(<50 km). There were no other reports that included information on the managing center
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location. Other center characteristics (e.g. type, size) were more frequently described in the
literature (see Section 2.5.4).
Household Income
The relationship between socio-economic status (SES) commonly defined as a combination of
education, income and occupation and glycemic control in children with T1D has not been
extensively studied. The children and adolescents in the U.S. SEARCH for diabetes study had
better glycemic control if their average household income was greater than $ 25, 000. Rosilio
and colleagues (1998) demonstrated the same in a French study. Subjects with poorer glycemic
control were more likely to have a parent with a monthly income < $ 1, 000 (Rosilio et al.,
1998). The effect of income was independent of ethnicity and parental education in those studies
(Pettite et al., 2009; McKenney et al., 2008; Rosilio et al., 1998).
Body Mass Index
Association of BMI and glycemic control varies across the studies. Worse glycemic control in
normal and underweight youth with T1D compared to obese subjects was reported in the study
of Petitte and colleagues (2009). However, increase in BMI was associated with higher A1C
level in other studies including the study of Cutfield and colleagues (2011). More studies are
needed to determine the relationship between BMI levels and achievement of glycemic control in
children and adolescents with T1D.
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Previous Control
Finally, early achievement of good glycemic control is predictive of future glycemic control
(Cutfield et al., 2011; Viswanathan, Sneeringer, Miller, Eugster, & DiMeglio, 2010). Shalitin et
al (2011) reported that in children with T1D diagnosed before age 6.5 years, mean A1C level in
the first year after diagnosis was a strong predictor of achieving target A1C levels in the
subsequent years independently of insulin regimen.

2.5.1 Longitudinal Patterns of Glycemic Control in Children and
Adolescents and Associated Factors
More recently, prospective cohort data on predictors of glycemic control in children and
adolescents with T1D have emerged. In an effort to improve the quality of diabetes care in
children and adolescents, associations of diabetes centers or study groups (such as the Hvidore
Study Group, the German Diabetes Quality Control Initiative and the US SEARCH for diabetes
study group) collected and started publishing longitudinal glycemic outcome data. For example,
Johannesen and colleagues (2008) compared the changes in glycemic control in a Danish
diabetic pediatric population between 1996 and 2006. The authors concluded that glycemic
control improved over the 10 years of follow up and a clear relationship between the number of
SMBG and improved control was shown. Glycemic control was significantly associated with
age, ethnicity and diabetes duration as well. Use of new insulin regimens and insulin analogs was
not found to improve glycemic control (Johannesen et al., 2008). In Sweden, data from a national
quality registry was followed prospectively as well. In this study, poor glycemic control was
associated with older age, high insulin dose, longer diabetes duration, and a higher number of
visits per year (Hanberger et al., 2008). The US SEARCH study has not yet published
longitudinal data on predictors of glycemic control.
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There are only a few other prospective longitudinal studies. The most recently published study
of 173 children shows that that factors significantly predicting achievement of the mean target
A1C (<7.5% as per ISPAD Guidelines) after 6.5 years of follow up were shorter diabetes
duration and lower A1C levels earlier in the disease (measured at 6 months, 1 and 2 years).
Gender, ethnicity, age at onset, presence of DKA at onset, mean number of SMBG and type of
insulin regime were not associated with meeting the A1C target. Mortensen and colleagues
(1997) found that glycemic control at 12 months post diagnosis was influenced predominantly
by ethnicity and the A1C level at the diagnosis (not found in the study of Shalitin and Philip)
while two other studies have found that female gender and greater BMI were also predictors of
higher A1C levels (Cutfield et al., 2011; Levine et al., 2001).

2.5.2 Diabetes Treatment and Predictors of Glycemic Control
Diabetes treatment related factors such as the number of insulin injections/day, use of an insulin
pump, insulin dose and type were considered potential determinants of glycemic control as well.
Interestingly, evidence on the association of glycemic control with type of insulin treatment
(number of daily injections or injections versus insulin pump) or with daily insulin dose per
kilogram of body weight have not shown a consistent association (Mortensen et al., 1997, 1998;
Rosilio et al., 1998; Shalitin & Philip, 2011). Moreover, the majority of studies have reported no
correlation of insulin treatment or the daily dose with glycemic control (Mortensen et al., 1998;
Dorchy et al., 1997; Danne et al., 2001). A weak association between higher insulin doses
(units/kg body weight), age of puberty, and glycemic control has been seen (Mortensen et al.,
1997; Hanberger et al., 2008; Urbach et al., 2004). De Beaufort and colleagues (2007) reported
that twice a day insulin regimen improves glycemic control compared to other regimen types
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including multiple insulin injections and continuous subcutaneous insulin infusion, the funding
likely explained by the improvement in diabetes education programs.

2.5.3 Other Variables
Other variables potentially important in predicting A1C were studied as well. For example,
Hanberger and colleagues (2008) explored if the higher number of clinical visits was correlated
with glycemic control and they found significant association. Similarly, Urbach and colleagues
(2005) reported higher A1C levels if participants attended the clinic at least 5 times in a year.
The presence of concomitant conditions such as celiac disease, autoimmune thyroiditis, or
asthma was not correlated with A1C (DeBeaufort et al., 2007; Shalitin & Philip, 2011). The
presence of DKA or antibodies at diagnosis also did not correlate with glycemic control (Urbach
et al., 2005; DeBeaufort et al., 2007; Shalitin & Philip, 2011).

2.5.4 Summary on the Predictors of Glycemic Control
In describing the results of the aforementioned studies on predictors of glycemic control, one
may find that outcome assessment differs across the studies. One of the early studies, the
International Multicenter study from the Hvidore Study group on Childhood diabetes, defined a
target A1C< 8% for children age 0-18 years. The cut off value was based on the achieved mean
A1C in the intensively treated group from the DCCT trial. Other studies, primarily conducted in
Europe, have defined the target A1C according to the International Society for Pediatric and
Adolescent Diabetes (ISPAD) Consensus Guidelines (specifically, an A1C< 7.5% for all
children). Finally, the SEARCH study from the US used the American Diabetes Association
(ADA) age-specific guidelines similar to the CDA guidelines used in this study (target values for
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A1C in relation to age are: <8.5% at age < 6 years, < 8.0% at age 6 to 12 years, < 7.5% at age 13
to 18 years, and < 7.0% at age 19+ years).
The variation of the findings among the studies emphasizes the complexity of diabetes
management in children under ‘real-world’ conditions. Risk and fear of hypoglycemia, quality of
diabetes education, dietary management, and social support are examples of factors influencing
glycemic control that are more difficult to study and less frequently reported. There is
convincing evidence that outcomes in children with T1D differ between diabetes centers around
the world (Mortensen et al., 1998; Daneman, 2009). The Hviodore Study group on Childhood
diabetes which included 21 pediatric centers from 17 countries in Europe, Japan and North
America (including the Hospital for Sick Kids in Toronto), examined blood glucose control
according to the treatment center. A substantial difference in the average A1C levels and the
rates of hypoglycemia were found between individual centers that was not explained by
prevailing insulin regimens and rates of hypoglycemia when adjusted for difference in various
socio-demographic factors (Danne et al, 2001). Craig and colleagues (2006) found a similar
difference between 96 pediatric centers from Asia and the Western Pacific Region, suggesting
that significant variability between the centers could be explained by difference in clinical care
and limited socioeconomic factors. Finally, Rosalio and colleagues (1998) have found that the
size of the pediatric center providing care to pediatric T1D patients affects diabetes outcomes.
Patients followed in academic pediatric diabetes centers managing at least 50 new T1D pediatric
patients a year had a lower mean A1C compared to the patients managed in the centers with
smaller patient volumes.
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While the reasons for the different glycemic outcomes across large, specialized, pediatric
diabetes centers are not entirely clear, it suggests that attitudes of treatment teams, diabetes selfcare, educational models, or patient satisfaction rather than insulin treatment type may be
responsible for the difference (Danne et al., 2001). This also suggests that determinants of
glycemic control in children and adolescents with T1D are center specific and it is important to
study those factors accordingly.

2.6 Delivery of Diabetes Care
Diabetes is primarily managed in the outpatient ambulatory setting. Even among the newly
diagnosed T1D pediatric patients, outpatient management including diabetes education has been
shown to be less expensive but equivalent or slightly better than inpatient education (Clar,
Waugh, & Thomas, 2006). The importance of regular, ambulatory diabetes care assessment for
younger patients with diabetes is essential to maintaining optimal glucose control and to monitor
for risk factors of acute and chronic complications (Laron et al., 1979; ISPAD Clinical Practice
Consensus Guidelines, 2009). As described in the previous section, care to a pediatric T1D
patient should be provided by specialist multidisciplinary diabetes care team consisting of a
pediatric diabetes specialist, diabetes nurse educator, dietitian, and pediatric social worker. The
multidisciplinary approach is strongly supported by the results of the DCCT as well (DCCT
Research Group, 1997). The team should recognize the family and child as an integral part of the
team. If a child with T1D does not have access to a specialized care center, they should be
followed by a physician who has access to resources and advice from the specialized team
(ISPAD Clinical Practice Consensus Guidelines, 2009). Following is the description of the
regional pediatric diabetes program at the Children’s Hospital, London Health Sciences Centre
(CH-LHSC).
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2.6.1 The London Pediatric Diabetes Program
The CH-LHSC diabetes team provides comprehensive care to over 1,400 children and
adolescents with diabetes and their families. The majority (95%) of these patients have type 1
diabetes (T1D) and 60% are adolescents. The multidisciplinary diabetes team is comprised of 3
pediatric endocrinologists, 3 nurse clinicians, 2 dietitians and 2 social workers with consultation
from a pediatric psychologist. Diabetes clinics are held twice weekly in the Pediatric Medical
Day Unit (PMDU) with weekly diabetes team meetings and monthly business meetings. Patients
are assessed and monitored at both the CH-LHSC and regional outreach clinics.
The regional pediatric diabetes outreach program was initiated in Sarnia in 1993, extended to
Chatham in 1997, and then Stratford in 2001. In addition to providing accessible clinical care,
this program has fostered collaboration and cooperation between the tertiary centre and
community-based health care professionals and has facilitated development of a collaborative
infrastructure for clinical research.
In the last 5 years the number of new patients with T1D referred to the CH-LHSC has ranged
from 70 to 93 per year. At diagnosis all patients are seen by one of the three pediatric
endocrinologists. Patients with new onset T1D in the Stratford area are also referred to the
tertiary centre for initial management. Patients with new onset T1D in Chatham and Sarnia are
initially managed in London and then referred for follow-up to the local outreach clinics. In 2009
there were 1,688 diabetes outpatient visits at the CH-LHSC and 475 diabetes visits at outreach
clinics in Chatham, Sarnia and Stratford.
The Children’s Hospital Diabetes Pump Program was initiated in 1999. The current patient
population using insulin pump range in age from less than 2 to 18 years old, and comprises
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approximately 41% of the total diabetes patient population. Patients are also offered the option of
continuous glucose monitoring and there were 60 insertions for continuous glucose monitoring in
2009.
Children and adolescents with T1D are followed every 3 to 4 months at the CH-LHSC and
outreach clinics by a cohesive team. This provides an excellent opportunity to contact the
patients and their caregivers about new trials as they arise. Active research studies are advertised
in the waiting rooms in the clinic and in a newsletter sent to families every 4 months. Since
1987, the Pediatric Diabetes Program has maintained a comprehensive database (Humabase) on
active T1D patients which has facilitated identification of potential subjects with the required
criteria for entry to clinical trials. Other initiatives and programs include a summer camp for
children with diabetes, Children’s Hospital Pediatric Diabetes Newsletter (“Islet Cell News”) for
children and families with diabetes, insulin pump therapy program, and an education program
providing workshops and education to families and health professionals in a community.

2.7 Summary
The incidence of T1D in children is rapidly increasing such that a doubling of T1D cases
worldwide is expected in 20 years (IDF, 2012). The rate of diabetes complications remains high
and, with the increasing incidence, it is becoming clear that the burden of T1D will continue to
increase.
While the etiology of T1D remains unknown, insulin therapy is a necessary lifesaving treatment.
Insulin therapy in combination with other lifestyle measures (diet, frequent home glucose
checking) is required to achieve strict glycemic control, which decreases the rate of long term
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diabetes-related complications. However, despite the availability of various insulin treatments,
this goal remains a challenge.
Management of diabetes in a pediatric population is complex and it includes interpersonal,
intrapersonal, community, institutional, and societal factors (Daneman, 2009). A child’s
cognitive development and abilities, age appropriate development and growth have to be
considered when treatment goals are set (ADA Clinical Practice Recommendations, 2011). An
individualized approach to treatment (including considerations such as insulin treatment induced
hypoglycemia, comorbid conditions, activity and diet) as well as family structure and support,
early education, availability of services, delivery of diabetes care and support of diabetes
programs are the major factors to be taken into account (Daneman, 2009). There is a multitude of
factors to consider when determining glycemic targets in pediatric T1D patients. Understanding
the factors that predict achievement of the target control is essential.

2.7.1 Research Questions and Objectives
The goal of this research was to answer the question whether there are demographic and diabetes
related clinical factors that can predict achievement of the target glycemic control in children and
adolescents with T1D in Southwestern Ontario. This was done by addressing the following three
main objectives:
Objective 1: To establish a pediatric diabetes cohort in Southwestern Ontario from 1998-2008
using a regional electronic clinical database for future studies in T1D.
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Objective 2: To describe and examine social, demographic, and clinical characteristics of this
cohort.
Objective 3: To identify factors predictive of glycemic control in the following three age groups:
< 6 years of age, 6-12 years, and > 12 years of age.

2.7.2 Significance of the Research
Attaining optimal glycemic control in children and adolescents with T1D is essential, however it
is difficult to achieve in many patients under ‘real world’ conditions. Improving understanding of
predictors of optimal glycemic control in the real world is therefore useful. It identifies children
and youth at highest risk of developing long term diabetes complications. In turn, early and
targeted intervention toward this group may improve T1D pediatric outcomes.
Evidence of predictors of glycemic control in children with T1D is limited. In particular, there
are no studies on determinants of glycemic control in Canada. Our study is the first study in
Canada to describe predictors of better glycemic control in a geographically defined area served
by a single specialized pediatric diabetes center.
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Chapter 3

3 Methodology
The following chapter will detail the methodology used in this thesis. It begins by providing the
overview of the data source used to derive the study population and is followed by the theoretical
framework for this thesis. Next is an explanation of measures and variables defined for this
study. The chapter will conclude with a brief overview of the statistical analysis used.
This study is the first step of program research to establish pediatric diabetes research database
and conduct exploratory analysis using available electronic clinical data.

3.1 Research Objectives
The overall goal of our research was to answer the question whether there are demographic and
diabetes-related clinical factors that can predict achievement of the target glycemic control (as
measured by the glycated hemoglobin or A1C levels) in children and adolescents with T1D in
Southwestern Ontario. Three specific objectives were addressed in relation to the research
question:
Objective 1: To establish a pediatric diabetes cohort in Southwestern Ontario from 1998-2008
using a regional electronic clinical database for future studies in T1D
Objective 2: To describe and examine social, demographic, and clinical characteristics of this
cohort.
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Objective 3: To identify factors predictive of glycemic control across three age groups: < 6 years
of age, 6-12 years, and > 12 years of age.

3.2 Pediatric Electronic Clinical Database
Since 1987, the CH-LHSC has employed an electronic clinical record called Humabase.
Humabase is a stand-alone system (i.e. no data is imported from other administrative, clinical, or
financial databases) that captures demographic and clinical information about pediatric diabetes
patients. An administrative assistant enters the data into Humabase directly from the clinical
notes and laboratory reports recorded at the time of the visit. Humabase produces a clinical
flowsheet that helps track diabetes care, including processes and outcomes. It is also a
comprehensive diabetes registry of pediatric diabetes patients in Southwestern Ontario. There are
1,606 patients currently registered and followed in the Humabase. We have assessed the
accuracy of the Humabase relative to an existing office patient paper chart in a validation study.
A random sample of 1% of all clinical encounters was selected and selected diabetes related
variables were assessed for accuracy of the Humabase. There were 35 variables potentially
available for validation, and 18 were selected based on their clinical significance. Three levels of
agreement were used to determine the accuracy, complete, partial and no match.
We demonstrated high levels of agreement between the Humabase data and reference standard.
The rate of complete matching ranged from 56-100% with median value of 96.4% completely
matched data.
A detailed description of Humabase, its history, data acquisition and validation can be found in
Appendix A.
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3.3 Thesis Framework
We used a literature review on determinants of glycemic control in T1D pediatric population to
identify demographic and clinical factors that were of interest (Figure 3.1). The following
variables were included in each model in this thesis: gender, age, distance from the treatment
center (London), average household income, diabetes duration, body mass index, and previous
glycemic control.
Gender
Glycemic control was shown to differ across gender (Palta et al., 1996; Mortensen et al., 1998).
Studies have found that female gender was correlated with poorer glycemic control (Petitti et al.,
2009; Danne et al., 2001; Gerstl et al., 2007). In a multicenter study from Austria and Germany
(included close to 30, 000 participants), females had a higher A1C than males at any age (Gerstl
et al., 2007). Orchard and colleagues demonstrated that there were gender variations in glucose
tolerance and insulin response among children and adolescents with T1D (Orchard et al., 1982).
Selected studies on longitudinal patterns of glycemic control have also reported significant
association of gender and glycemic control with females exhibiting worse glycemic control
compared to males. (Daneman et al., 1981, Klein, Slap, Elster, & Schonberg, 1992; Cutfield et
al., 2011).
Age
Studies have demonstrated that age and glycemic control were strongly correlated (Rosilio et al.,
1998; Danne et al., 2001; Petitti et al., 2009). Glycemic control worsened as age increased with
worst control at pubertal age. This relationship was observed consistently across all studies. It
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appears that there are multiple factors responsible for this complex relationship including:
progressive loss of beta cell function in the early years of diagnosis, potential weight gain as a
result of insulin treatment, insulin resistance that develops at adolescence, and a myriad of
psychosocial factors such as decreasing compliance with treatment and diet reported during
teenage years (Mortensen et al., 1996; Gerstl et al., 2007; Daneman, 2006). Palta and colleagues
(1996) have shown in their study on longitudinal patterns of glycemic control in T1D subjects
from the Wisconsin Diabetes registry that there was a curvilinear relationship between age and
A1C. In this study which included 501 T1D subjects age 0-20 followed for up to 4.5 years after
diabetes diagnosis, the authors included the quadratic age factor but there was no information on
whether it improved the fit of the prediction model (Palta et al., 1996). Subsequent studies,
including those with the largest study population to date (Multicenter international Hviodore
study, multicenter Austrian and German study and Search in Diabetes US study) have all
assumed a simple linear relationship between age and A1C. In our study, we included age as a
simple linear term.
Distance from the Treatment Center
It has been long recommended that pediatric diabetes care be provided by a specialized center
(CDA Practice Guidelines, 2008). However, numerous studies have shown that the level of
glycemic control varied according to location and type of the medical center (Mortensen et al.,
1997; Rosilio et al., 1998; Danne et al., 2001; Hanberger et al., 2008). In a nationwide study in
France, Rosilio and colleagues (1998) found that glycemic control improved if the family lived
close (i.e. < 50 km) to the managing center. The subjects included in our study were all part of
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the same tertiary specialized pediatric diabetes care program at CH-LHSC, but distance of family
residence to the care center varied between subjects and as such was included as a variable.
Household Income
A cross sectional study in French children demonstrated that A1C <8% was more likely if the
average monthly family income was > $ 2,000 (Rosilio et al., 1998). In the SEARCH study,
lower annual household income (< $ 25, 000) was associated with worse glycemic control even
when adjusted for other variables such as ethnicity and parental education (Petitti et al., 2009).
Acharya and colleagues (2008) found a negative but statistically non-significant relationship
between glycemic control and deprivation score (which included income, employment, housing,
health, education and access). Interestingly in this Scottish study, investigators also examined the
effect of deprivation scores with postcodes. With each shift per quartile they found that A1C rose
by 0.2%. Thus, patients living in the least affluent areas had 0.8% higher A1C than those in the
most affluent area, although this did not reach statistical significance (Acharya et al, 2008).
Diabetes Duration
Previous studies demonstrated a positive correlation between diabetes duration and glycemic
control (Rosilio et al., 1998; Petitti et al., 2009; Danne et al., 2001). An increasing duration of
diabetes was significantly associated with poorer control demonstrated in a population-based UK
study of 1,742 children and young people with T1D. The authors of this study reported a 0.08%
rise in A1C for every additional year of diabetes duration (McKinney et al., 2008). The pattern of
worsening glycemic control with increased duration of diabetes is due in part to progressive loss
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of beta cell function but also contributing may be the difficulty in maintaining motivation for
daily diabetes care over time (Petitti et al., 2009; Scholin et al., 2004).
BMI
The children and adolescents in the SEARCH for diabetes in youth study had poorer glycemic
control if they were classified (<85th percentile) as underweight (Petitti et al., 2009). However,
Acharya and colleagues (2008) demonstrated improved glycemic control in males and a
statistically non-significant but similar trend in female T1D participants with lower BMI
standard deviation scores in a study of 255 T1D subjects in Scotland. BMI was significantly
associated with glycemic control in the study by Danne and colleagues. Those authors
demonstrated improved glycemic control with higher BMI (Danne et al., 2001; Hanberger et al.,
2008). It is not yet clear what the relationship between glycemic control and BMI is. Petitti and
colleagues suggested that in children with lower BMIs, pancreatic beta cell function and insulin
section were preserved over longer periods and that this favors the negative relationship (Petitti
et al., 2009).
Previous Control
Finally, A1C values at diagnosis and 6 months after diagnosis have been found to be positively
correlated with the achievement of glycemic control at 24 months post-diagnosis (Shalitin &
Philip, 2011; Cutfiled et al., 2011). While statistically significant, this relationship was not found
to be strong. Other reports have described the phenomenon of ‘metabolic tracking’, suggesting
that earlier achievement of glycemic control may lead to a better control long-term (Edge, James,
& Shine, 2010).
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Demographic variables
Gender
Age
Ethnicity

Socioeconomic variables
Family structure
Parental education
Household Income
Distance from the treatment center
Diabetes care center/ provider type

Clinical variables
Age at diagnosis
Diabetes duration
Home blood glucose monitoring
Hypoglycemia episodes
DKA episodes
Previous A1C/glycemic control
Insulin regime
Insulin dose
Pubertal Stage
Body Mass Index

Figure 3.1: Determinants of Glycemic Control

Outcome variable: A1C
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3.4 Ethics Approval
The Western University Health Sciences Research Ethics Board approved this study (Appendix
B). Only secondary data sources were used in the study and therefore no informed consent was
required.

3.5 Study Population
The target population consisted of all pediatric patients (ages 1-20) in the Southwestern Ontario
region that are diagnosed with Type 1 diabetes mellitus, seen by the specialized pediatric
diabetes care team at least once and with an A1C measurement entered in the pediatric diabetes
clinical electronic database.
We retrospectively examined the Humabase database for the period January 1, 1998 to August 1,
2008. The start year chosen was the year (1998) when the first Canadian Diabetes Association
Practice Guidelines which recommended the current model of care were released. The study
cohort was examined in the 10 years period. Included were patients with permanent residence in
the Southwestern Ontario area (from Lake Erie to the Bruce Peninsula, which includes Bruce,
Elgin, Grey, Huron, Middlesex, Norfolk, Oxford and Perth counties). Subjects were followed at
the tertiary pediatric diabetes program at Children`s Hospital, London Health Sciences Centre as
well at the two outreach clinics in Sarnia and Stratford. Data is entered centrally at the Children’s
Hospital in London, where it is stored.
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3.5.1 Definition of Type 1 Diabetes
Diagnosis and diabetes type were determined by a pediatric endocrinologist and recorded in a
patient paper chart from which the data were transferred to the Humabase database. The
diagnosis of T1D was recorded in the Humabase at the time of the patient’s first entry (at the
diagnosis) in the database.

3.6 Study Design
A retrospective cohort study was conducted using the regional pediatric diabetes clinical
electronic database. All eligible subjects who were entered in the Humabase at the time of
diabetes diagnosis were identified and followed between 1998 and 2008. Subjects had variable
length of follow up and were entered in the study at any point over the 10 years of observation.
Once study participants were identified, the study cohort was stratified into three age groups
based on age-appropriate glycemic targets of the Canadian Diabetes Association Clinical
Practice Recommendations (see Table 1).
The three age strata were treated as the cross sectional subsets. Only the most recent A1C value
was selected for the analysis. A subject could have been included in each of the three age strata.
Therefore, each subject contributed between 1 and 3 A1C values that were analyzed separately
and according to the age category. Subjects’ baseline characteristics were collected at the time of
the first entry into the database, and while this may precede the study period (i.e. registered prior
to 1998), it was entered at the time of diagnosis and is as such defined by the study objective.
The study design is graphically depicted in Figure 2. The circled values are the outcome
measures (A1C) recorded at the visit and were included in analysis. Non-circled values are A1C
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3.6.2 Exclusion Criteria
Excluded were subjects that had no A1C value recorded in the electronic database and those with
missing predictor variables (see also Figure 4.1).

3.7 Outcome Measures
Glycated hemoglobin (A1C) was the outcome variable used to determine glycemic control. A1C
values were used to determine achievement of recommended treatment targets. A1C values,
measured from either capillary or venous blood sample were included.
There were two main methods of measuring A1C: point of care using capillary sample and
laboratory venous A1C sample (requires venous blood draw). Point-of-care (POC) instruments
for A1C are used in the pediatric diabetes programs in Canada for the measurement of glycated
hemoglobin. At CH-LHS pediatric diabetes program, the A1C levels is done by the POC testing
at every clinic visit using the Bayer DCA 2000 analyzer.
POC instruments for A1C provide relatively quick results and minimize patient inconvenience.
Studies have confirmed that immediate feedback of A1C levels improves glycemic control in
T1D (Cagliero, Levina, & Nathan, 1999; Ferenczi, Reddy, & Lorber, 2001; Miller et al., 2003).
The MetroNet study comparing laboratory and point of care A1C has found a good correlation
between venous and capillary samples, with a correlation coefficient reported to be 0.884
(Schwartz, Monsur, Hammad, Bartoces, & Neale, 2009). In the same study, mean A1C of the
two methods (POC and laboratory) differed by 0.15% (7.38% vs 7.53%) (Schwartz et al., 2009)
The A1C measure was entered into Humabase regardless of the measurement method. There is
no indication or method that allowed us to distinguish whether the measurement is point-of-care
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or laboratory venous measurement. Therefore, we included all available A1C measurements.
Based on the current local practice it was expected that the majority of samples were measured
as point-of-care with each visit, and only a minority may possibly be venous samples. Even if the
proportion of the venous samples was higher than predicted, it was not expected to introduce
measurement bias, as described above the correlation between the samples is high and difference
in values not greater than 0.5% which is considered clinically significant change. A yearly
calibration of the POC instrument (i.e. Bayer DCA 2000) is done locally and 0.5 % difference
between venous and capillary sample was reported in 2011.

3.8 Variable Definition
3.8.1 Sex
Self or parent reported as either female or male. Gender was specified as a binary variable, with
0 representing females and 1 for males.

3.8.2 Age
Age (years) of the subjects at the date when the outcome is selected (i.e. age at A1C test used in
the final analysis). Age is constructed as a continuous variable measured in completed years.
Age is restricted to 1-20. Although the Canadian Diabetes association Clinical Practice
Guidelines define a child as individuals 0-18 years of age (CDA Expert Committee, 2008), our
study set the upper limit to age 20 years as occasionally a patient is followed by the pediatric
diabetes program beyond age 18 years and could therefore contribute further data to Humabase.
The age values for this study were derived as follows: the date of birth was entered at the initial
entry (first visit with the program) into Humabase. At the initial and each subsequent clinical
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visit, the date of visit was entered as well (both in the same format, YYYY/MM/DD). The age of
each subject in years was then calculated based on a given visit date and birth date.

3.8.3 Location
Distance (km) between London (CH-LHSC) and the self-reported city of the permanent residence
identified at the first visit with pediatric diabetes program. Location was constructed as a
categorical variable using distance from Children`s Hospital, London Health Sciences Center in
London to subject’s permanent residence entered at the first visit to the program. Permanent
residence city and postal code available in the database were used to calculate distance. Distance
in km between London (reference value) and city of residence was calculated using the Google
map tool. A variable was created for residents of towns and cities within 50 km radius from
London (reference) and all other communities (distance greater than 50 km from London). The
cut point was chosen based on the observation that worsening glycemic control was associated
with > 50 km distance from a university based treatment center (Rosilio et al., 1998).
Furthermore, the univariate analysis also indicated that the numbers of subjects for these groups
were relatively equally distributed.

3.8.4 Income
The mean total income of households in dollars (based on the year 2000 earnings). This was
constructed as a categorical variable using Forward Sortation Area (FSA) to derive mean
household income. The postal code is a six-character code, defined and maintained by Canada
Post for the purpose of sorting and delivering mail. The first three characters of the postal code
identify the FSA. For the census, the postal code is captured for all households from the address
information provided by the respondent. We used the FSA and linked it to the Statistics Canada
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data to obtain mean household income at the postal code level. The most recent data available at
the Western University Equinox library system uses 2001 Census data. A dummy variable was
created for average household income < $ 57, 000 (reference) and > $ 57,000. This cutpoint was
determined based on the median income in our data set.

3.8.5 Diabetes Duration
Length of diabetes duration, from the diagnosis to the date when the outcome (A1C) has been
selected (years). This was constructed as a continuous variable. Duration of diabetes had to be
derived using date of diabetes diagnosis. The calculation could not be automatically completed
by the Humabase program. Furthermore, date of diabetes diagnosis was entered in the Humabase
using different formats and units of measurement. For example, the diagnosis date often only
noted a year, sometimes a full date and occasionally was only entered as the age of diagnosis. If
the year of diagnosis was entered, then that year was extracted from the most recent visit date
and duration in years in calculated as Year (most recent visit) -Year (diagnosis). As the
development and diagnosis of T1D in children and adolescents is a precipitous and clinically
obvious event, it was a reasonable assumption that the date of the initial visit was the date of
diagnosis. Duration of diabetes was then calculated as Year (most recent visit)-Year (initial
visit).

3.8.6 Body Mass Index
Derived variable from the available height and weight on each subject at the first visit with the
pediatric diabetes program (kg/m2). This variable was modeled as a continuous variable using
participants’ height and weight at the first visit to the pediatric diabetes program. Height and
weight were sometimes entered into database without specifying units of measurement.
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Exploratory analysis was done assuming measurement in either metric (kg and meters) or
imperial (pounds and inches) units. When checked for the range, BMI calculation using imperial
units was excluded as it resulted in values well below the expected range (e.g. values between
0.01-1.0). Therefore, BMI was calculated using following formula: weight (kg) /height (m2). In
addition, BMI z scores were derived using U.S. Centers for Disease Control and Prevention
(CDC) growth charts data for children age 2-20 to determine age and gender specific BMI z
scores.

3.8.7 Previous Glycemic Control
Achievement of glycemic control (target A1C) in the previous time period (binary).
A variable was created based on the achievement of target A1C in the previous time period. This
variable was included only in the middle (age 6-12 years old) and oldest (> 12 years old) age
category subsets and corresponding regression models. For example, if a subject was followed
from birth to age 20, then she/he belonged in each of the three age category subsets (i.e. age <6,
6-12 and age>12) at a different time period. To each of the 3 age strata, this subject contributed
one A1C value that was (or was not) at target. Thus, a new variable (i.e. previous glycemic
control) was created and included in analysis for the subsequent age category model. Whether
the A1C was at target when a subject age was between 6-12 years old was included in a model
when the subject age was 12 years and older.

3.9 Statistical Analysis
Demographic and clinical variables for the complete cohort are described as mean ± standard
deviation (SD) or proportion where applicable.
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3.9.1 Bivariate Analysis
Bivariate analyses were carried out to establish relationships between the outcome and predictor
variables. For categorical variables a Chi-square test was performed and odds ratio were given
along with the results of the significance test. For continuous predictors, maximum likelihood
regressions were performed for each variable.

3.9.2 Multivariable Analysis
For each age category stratum, a separate multivariable logistic regression analysis was used to
assess the effect of age, gender, duration of diabetes, distance from the pediatric diabetes center,
average household income, BMI, and previous control on the future achievement of glycemic
control. Exploratory analyses were conducted using bivariate and multivariable methods. To find
a linear model that best predicted the glycemic control from the above 7 independent variables,
backward and forward selections were used with entry and exit significance level of p=0.2.
Effect measures were reported as unadjusted odds ratios (ORs) with 95% confidence intervals.
Comparisons of the distributions of variables for subjects with missing and non-missing data
were obtained using Chi-square tests for categorical and t-tests for continuous data.
The general logistic multivariable model used for all 3 age strata was as follows:
Ln (Yi) =β0 + β1(Sex) + β2(Age) + β3(Location) + β4(Income) + β5(Diabetes Duration) +
β6(BMI) + β7(Previous control)*
where Yi is target glycemic control of the ith subject.
*Previous control term was included only in the second and third model (stratum 6-12 years old
and > 12 years old).
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Odds ratios representing the odds of achieving glycemic control in each of the three age strata
was calculated as follows:
OR = eβi
Linear relationship between outcome and predictor variables were assumed.
All statistical analyses were completed using SAS version 9.3. (SAS Institute, NC).

3.9.3 Missing Data
Subjects with missing data were excluded from analyses. Comparisons of the distributions of
variables for subjects with missing and non-missing data were completed.
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Chapter 4

4 Results
This chapter presents the results of this thesis research. It begins with a description of
determination of the study cohort, followed by a description of the cohort. Results of the
bivariate and multivariable logistic regression analysis determining predictors of glycemic
control are then discussed. Additional analysis and estimation of the fit of our model complete
this chapter.

4.1 Study Cohort
Between January 1, 1998 and August 1, 2008, a total of 1,309 subjects with diabetes registered in
the Humabase were identified. These subjects accounted for 19,805 visits in the same time
period. After applying the study inclusion and exclusion criteria, the final study cohort included
996 patients. These patients had 1,381 visits with complete data for inclusion in final analysis.
The flowchart describing the study cohort can be seen in Figure 4.1.
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Pediatric diabetes patients registered in
Humabase
N=1,490 (24,906 visits)

NOT ASSESSED FOR ELIGIBILITY
Patients followed up to 1998

N=177

Duplicate records

N=4

ASSESSED FOR ELIGIBILITY
N=1,309 (19,805 visits)
NOT ELIGIBILE
Type 2 Diabetes

N=21

Cystic fibrosis related diabetes

N=1

Age > 20

N=3

TOTAL ELIGIBILE
N=1,284 (12,287 visits)
EXCLUDED
Duration of follow up < 1 year

N=110

Missing Data

FINAL SAMPLE
N= 996 (1,381 visits)

Figure 4.1 Study Sample Size

A1C

N=104

BMI

N=57

Postal Code

N=17
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Three age category specific subsets were created using the complete cohort. The first subset
included all subjects whose age at the time of a clinical visit was < 6 years old, the subsequent
category included children whose age was between 6 and 12 years at the time of the recorded
visit, and the final subset included those who were 13 years and older. Once the subsets based on
the age categories were created, the most recent A1C value was selected. The following are the
number of subjects included in each of the subsets, subset1 (age < 6 years) n=123, subset2 (age
6-12 years) n=453, and subset3 (age >12 years) n=805 (Table 2).
Table 2: Age Category Subset Size
Age category (years)

Number of subjects

<6

123

6-12

453

> 12

805

Total

1,381

4.2 Cohort Characteristics
The mean age of the entire cohort (± SD) was 15.1 ± 3.5 years. The youngest participant was 2.8
years old and the oldest was 19.9 years of age. There were 52.2 % (n=520) male and 47.8%
(n=476) female subjects included in the cohort. The mean duration of diabetes diagnosis was 8.9
± 4.3 years. Fifty five percent (n=546) subjects lived within 50 km from London, while 45 %
(n=450) subjects lived further than 50 km from London. Among all the subjects only 3.7%
(n=37) lived further than 200 km from London. The distance from London ranged from 3.4 km
to 996 km. The average household income was $59,764 ±10,758 dollars and 41.7% (n=415)

46

subjects had average household income of less than $57,000. There were only 1.1 % (n=11)
subjects whose average household income was above 100,000 dollars. The BMI mean z-score of
the entire cohort was 0.68 ± 0.83. The BMI z scores range from -3.44 to 2.66. The mean weight
of the cohort was 61.9 ± 19.5 kg. The number of visits for the entire cohort ranges from 1 to 40,
with a mean number of visits that was 2.3 ± 12.6.
Clinical characteristics of the cohort are described in Table 3.
Table 3: Characteristics of the Complete Cohort

Variables

Age (years)

15.1 ± 3.5

% Male

52.2

% Distance from London > 50 km

45.0

% Average Household Income > $ 57,000

58.3

Duration of Diabetes (years)

8.9 ± 4.3

Body Mass Index z-score

0.68 ± 0.83

Data are mean values ± SD or frequencies.

4.3 Glycemic Control
The total cohort included 996 subjects who contributed 1,381 A1C values that are included in the
analysis. The average A1C of the entire cohort was 8.7 ± 1.6%. The mean A1C values for the
each of the analyzed subsets were as follows: 8.3 ± 1.0 % in the < 6 years of age, 8.3 ± 1.2 % in
the 6-12 years of age, and 8.8 ± 1.7 % for the oldest (13-20 years) age category. The best overall
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control was achieved in the youngest age category subset, with 62.6% participants (n=77) having
A1C values that were in the recommended range. In the middle age category, 43.5% participants
(n=197) achieved the target A1C, in the oldest age group, 9.8% (n=79) were in the target A1C
range. Table 4 details the achievement of the glycemic control according to the age category.
Included in the table are the target A1C values for the reference for each of the age categories.

Table 4: Achievement of the Glycemic Control According to the Age Category

Age category (years)

Proportion of subjects with A1C
in the recommended range %
(n)

Recommended A1C level

<6

62.6 (77)

< 8.5%

6-12

43.5 (197)

< 8.0%

>12

9.8 (79)

< 7.0%

4.3.1 Characteristic of the Three Age Cohorts
Table 5 describes characteristics of the three age cohorts. In each of the three subsets there were
more males, 56.9% (n=70) subjects included in the youngest subset, 52.5% (n=238) of those
with age between 6 and 12 years, and 50.8 % (n=409) in the subset when their age was 12 and
older. Mean weight in each of the subsets was 21.8 ± 3.9, 42.2 ± 11.9, and 68.3 ± 14.7 kilograms
with subsequent BMI in each of the subsets as follows: 17.1 ± 1.1, 19.7 ± 1.1, and 23.9 ± 4.0
kg/m2 from the youngest to oldest. These BMI values correspond to the following BMI z scores:
1.1 ± 0.6, 0.6 ± 0.8, and 0.7 ± 0.8 from the youngest to the oldest category. Mean household
income was $ 61,698 ± 10,251 for the participants included when age belonged to the category <
6 years of age, $ 59,992 ±11,031 and $ 59,645 ±10,531 in the subsequent subsets.
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Table 5: Characteristics of the Three Age Cohorts
Age < 6 years

Age 6 – 12 years

Age > 12 years

n

123

453

805

% Male

56.9

52.5

50.8

5.4 ± 0.7

11.0 ± 1.4

16.5 ± 1.8

% Distance from London > 50 km

45.5

47.2

46.3

% Average Household Income
> $ 57,000

68.3

58.5

57.8

Diabetes duration (years)

2.4 ± 1.1

6.0 ± 2.7

9.9 ± 4.1

Body Mass Index (kg/m2)

17.1 ± 1.1

19.7 ± 1.1

23.9 ± 4.0

BMI z-score

1.1 ± 0.6

0.6 ± 0.8

0.7 ± 0.8

Mean A1C (%)

8.3 ± 1.0

8.3 ± 1.2

8.8 ± 1.7

Variables

Age (years)

Data are mean values ± SD unless otherwise indicated.

4.4 Predictors of Glycemic Control
4.4.1 Bivariate Analysis
The results of bivariate analysis exploring the relationship between each predictor and the
achievement of glycemic control across all 3 age categories are shown in Table 6.
In the youngest age group, participants who lived closer to London (< 50 km) were more likely
(OR=0.35 95% CI 0.16-0.74) than participants who lived further away (>50 km) to achieve
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target glycemic control. Gender, age, income, diabetes duration, and BMI were not significantly
associated with achievement of glycemic control for subjects 6 years and younger.
There were no statistically significant associations between variables included in the study and
achievement of glycemic control seen in 6-12 years old participants.
Males are more likely to achieve target glycemic control than females. The odds of achieving
target glycemic control in females were approximately one half as great as in males age 12 years
and older (OR=0.47 95% CI 0.29-0.77). With longer duration of diabetes, the odds ratio of
achieving target glycemic control continually increased in subjects age 12 years and older
(OR=1.13 95% CI 1.06-1.21). Similarly, the odds ratio of achieving target glycemic control in
subjects 12 years and older was higher as age increased (OR=1.21 95% CI 1.04-1.41). The
likelihood of achieving target glycemic control was higher if BMI at diagnosis was hiher as well
(OR=1.06 95% CI 1.01-1.12). Finally, adolescents who had achieved optimal glycemic control
before they were 12 years old, were almost 2 times more likely to have good glycemic control
compared to the subjects who did not achieve target control at younger age. There were no
significant association between household income and distance from London and glycemic
control for the over age 12 years.
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Table 6: Odds Ratios for the Relationship between Demographic and Clinical Variables
and Glycemic Control (Results of Bivariate Analyses)
Model 1 (Age < 6)

Model 2 (Age 6 – 12)

Model 3 (Age > 12)

n=123

n=453

n=805

Gender
Male
Female

1.00
0.55

1.00
1.06

1.00
0.47*

Age (years)

1.29

0.99

1.21**

Distance from London
< 50 km
>50 km

1.00
0.35*

1.00
0.89

1.00
1.09

Household Income
< $57,000
>$57,000

1.00
0.77

1.00
1.15

1.00
1.15

Diabetes duration
(years)

0.89

1.04

1.13*

Body Mass Index
(kg/m2)

1.13

1.03

1.06**

1.00
1.23

1.00
1.95*

Number of
subjects
Variables

N/A
Previous Control
No
Yes
Note: Odds Ratio of 1.00 denotes reference category.
* denotes p<0.01
** denotes p<0.05
N/A – not applicable

4.5 Predictors of Glycemic Control - Multivariable Logistic
Regression Models
Determinants of glycemic control were assessed using three separate multivariable logistic
regression models for each of the age categories. Location was the only statistically significant
predictor of the achievement of glycemic control among subjects less than 6 years old [OR= 0.35
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(0.16-0.74)]. There was no association of glycemic control and selected demographic and
clinical factors for the subjects whose age was between 6 and 12 years old. In contrast, several
variables were found to be associated with glycemic control in the oldest age category. The ORs
for covariates of interest for each of the age categories are shown in Table 7.
Table 7: Results of Stepwise Regression Analyses of Demographic and Clinical Variables
Associated with Glycemic Control
Model 1
(Age < 6 years)

Model 2
(Age 6 – 12 years)

Model 3
(Age > 12 years)

n=123

n=453

n=805

Gender
Male
Female

-

-

1.00
0.45* (0.27-0.74)

Age (years)

-

-

Number of
subjects
Variables

Distance from London
< 50 km
>50 km

-

-

-

-

-

Diabetes duration
(years)

-

-

1.12* (1.05-1.20)

Body Mass Index
(kg/m2)

-

-

1.07** (1.01-1.13)

Household Income
< $57,000
>$57,000

1.00
0.35* (0.16-0.74)

-

N/A
Previous Control
No
1.00
Yes
1.25 (0.92-1.71)
Note: Data are Odds Ratios with 1.00 denoting reference category.
* denotes p<0.01
** denotes p<0.05
- denotes that variable was not selected in final model
N/A – not applicable

1.00
1.54 (0.98-2.43)
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Included in the final model for 12 years and older age category were gender, diabetes duration,
BMI and achievement of the previous control. Females were only a half as likely as males to
achieve target glycemic control (OR=0.45 95% CI 0.27-0.73). The odds of achieving target
control were higher with longer diabetes duration (OR=1.12 95% CI 1.05-1.20). The odds of
achieving target glycemic control was higher if BMI was higher at diagnosis in subjects age 12
and older (OR=1.07 95% CI 1.01-1.58). There was no statistically significant association
between the previous glycemic control and the achievement of target glycemic control in our
model for subjects with T1D age 12 years and older.

4.6 Missing Data
There were 104 subjects with missing information on A1C level, 57 on BMI, and 17 on postal
code. Among the excluded subjects with missing data 7.8% (n = 14) were age < 6 years old,
25.8% (n = 46) were age 6-12 years, and 66.3% (n = 118) were older than 12 years. The subjects
with missing data were on average younger than subjects with non-missing data (12.9 vs. 15.1
years, p < 0.0001) and had significantly shorter duration of diabetes (2.4 vs. 8.9 years, p <
0.0001). Subjects with missing data who were excluded from the analysis were more likely to
live > 50 km from London compared to the entire cohort (OR = 1.74 95% CI 1.33-2.29). There
was no difference in gender distribution or BMI between subjects with and without missing data
(Table 8).
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Table 8: Comparisons of the Distributions for Subjects with Missing and Non-missing Data
Variables

Subjects with Non-missing Data

Subjects with Missing Data

52.2

50.7†

Age (years)

15.1 ± 3.5

12.9 ± 5.3*‡

Diabetes Duration (years)

8.8 ± 4.3

2.4 ± 2.3*‡

% Distance from London
> 50km

45.0

58.7*†

Body Mass Index (kg/m2)

22.9 ± 4.2

23.2 ± 6.3‡

% Male

Data are mean values ± SD unless otherwise indicated.
* denotes p<0.001.
†
P-value obtained using Pearson chi-square test to test proportions in each category.
‡
P-values obtained using two sample t-test.

4.7 Further Analysis
To assess for possible collinearity between variables to explain possible change in the
significance of the predictive factors (age and diabetes duration or duration of diabetes and
previous control), variance inflation and tolerance factors were calculated via multiple
regressions for each variable. No value greater than 10 was observed suggesting no significant
collinearity. Separate analyses were carried out using calculated BMI and derived BMI z scores.
There was no difference in the final models, as both BMI and BMI z scores were significant
predictors of glycemic control only in the subset including the >12 years old age category.
Finally, presented in this chapter are the results of backward selection procedure in selecting the
multivariable regression model. Forward analysis was completed as well however the results
remained unchanged (Appendix C).
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4.8 Summary of the Results
A retrospective cohort of pediatric T1D subjects between ages 1-20 was analyzed for predictors
of glycemic control based on the A1C level. The total cohort included 996 subjects who
contributed 1,381 A1C values in the final analysis. In the complete cohort, there were similar
numbers of male and female participants (520/476), with an average duration of diabetes of 8.9
years. The majority of participants lived within 50 kilometers of London (55%) in a household
with average income of grater than $ 57,000. Of all the A1C values included in analysis, 1152
(83.4%) did not meet the recommended age specific glycemic target criteria.
The results of unadjusted odds ratios demonstrated that age, gender, duration of diabetes, body
mass index, and previous glycemic control were predictors of the achievement of glycemic
control among patients >12 years old, while the distance from London was the only significant
predictor for the youngest patients (< 6 years old). In multivariable analysis, gender, diabetes
duration, and body mass index significantly predicted A1C levels but only in the age group for >
12 years old. Age and previous control did not significantly predict the achievement of target
glycemic control in multivariable analysis among patients age > 12 years old.
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Chapter 5

5 Discussion
Type 1 Diabetes is the second most common chronic disease of childhood. Early achievement of
glycemic control is a major goal of diabetes treatment as it prevents long term diabetes
complications. However, achievement of this goal remains a challenge. It has been shown that
mean A1C values (a measurement of glycemic control) remains above the recommended targets
in children and adolescents with T1D around the world.
Multiple cross sectional studied have identified demographic and clinical variables associated
with glycemic control in children and adolescents with T1D. However, a minority of cohort
studies in the past 15 years studied possible predictors of glycemic control. Those studies
included small numbers of subjects (<500) and were limited to children age 16 years and
younger. Only recently have longitudinal data including unselected population of children and
adolescents with T1D become available. The results of these studies indicated a persistent
difference in the level of glycemic control across various centers despite the same treatment
approach at each of the centers. This difference has not yet been explained as the longitudinal
data from individual centers within each study are lacking.
The goal of our research was to answer the question whether there are demographic and
diabetes-related clinical factors that can predict achievement of the target glycemic control (as
measured by the glycated hemoglobin or A1C level) in children and adolescents with T1D in
Southwestern Ontario.
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5.1 Summary of Key Findings
We examined selected factors that predict achievement of target glycemic control under real
world conditions in children and adolescents with T1D. Participants in our study were followed
at a single tertiary pediatric diabetes center in London that provides care to all newly diagnosed
T1D children and adolescents in Southwestern Ontario. Study participants were followed for 10
years.
Our results revealed that predictors of achievement of glycemic control were not the same across
three prespecified age categories. In the bivariate analysis we identified significant predictors of
achievement of glycemic control in two groups of subjects - those less than 6 years old and
subjects over 12 years of age. Multivariable logistic regression of predictors of glycemic control
confirmed the same finding. The only significant predictor of target A1C in the youngest
subjects (< 6 years old) was shorter distance from London, i.e. within a 50 km radius of the
specialized pediatric diabetes program. Male gender, longer duration of diabetes and higher BMI
were significant predictors of achievement of glycemic control in patients over 12 years old. We
did not identify significant predictors of glycemic control for the participants between 6 and 12
years old.

5.1.1 Glycemic Control
Despite multidisciplinary specialty care provided by the experienced diabetes team, the overall
glycemic control in our cohort was suboptimal with a mean A1C of 8.7 %. Although
unsatisfactory, this finding is comparable to other pediatric T1D populations. For example, the
mean A1C among US children from the SEARCH for diabetes in youth study was 8.2% (Pettiti
et al., 2009). In the international Hvidore Study, the mean A1C was 8.6% (Mortensen et al.,
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1997) and in the recent 2010 Manitoba pediatric diabetes program report, the mean A1C was
8.9% (2010 Winnipeg Child Health Program Annual Report, n.d.). Our study found that only
17% of included A1C values were at or below the target A1C level for children and adolescents
recommended by the 2008 Canadian Diabetes Association Practice Guidelines.
Our results could be affected by a selection bias. We included in the final analysis only A1C
values that were recorded at the clinical visit. This meant that subjects who were lost to medical
follow up were not included in the analysis. Other studies have shown that adolescent and young
adults with T1D who dropped out of the medical care system had worse glycemic control and
higher A1C values compared those who had regular medical follow up (Osgood et al., 2010). It
is therefore likely that our results underestimated A1C level in our cohort.
The proportion of individuals achieving target glycemic control decreased across the age
categories in our study. This implies that there is either a worsening of glycemic control with age
or that later age of diagnosis contributes to suboptimal glycemic control. Longitudinal studies in
children and adolescents with T1D have demonstrated worsening glycemic control during the
teenage years. Pubertal hormonal changes that antagonize the action of insulin and other
psychosocial factors (deliberate insulin omission for weight control, experimentation with
alcohol and drugs, etc) are likely explanations. Moreover, an increasing rate of obesity with
increased insulin resistance negatively affects diabetes control. Future studies are planned to
answer this issue.

5.1.2 Predictors of Glycemic Control
We found that children diagnosed with T1D before age 6 years and followed beyond the first
year of diagnosis were more likely to achieve target glycemic control if they lived within 50
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kilometers of the specialized diabetes program compared to children who live further away.
These results confirm the findings of Rosilio and colleagues (1998) that children who live closer
to the treating center have better glycemic control. This suggests that inequality of access to the
specialized diabetes program may exist based on geographic location. At the same time, in our
study we did not control for the number of clinical visits and are not able to determine whether
participants who live further away from London have decreased frequency of clinical visits due
to limited access. We postulate that in this youngest age group, caregivers may rely more on the
local non-specialized diabetes resources. We did not see a relationship between distance from the
treating center and glycemic control in older children (i.e. children diagnosed and/ or followed
beyond age 6 years).
We found no significant predictors of glycemic control in the subset of children followed by the
pediatric diabetes program between the ages 6 and 12 years. Our model had limitations in that
factors not included in our study may be responsible for this finding. Future studies are needed to
address the question as to whether some factors are more important in some and not other age
categories.
Our study finding was that male gender, longer diabetes duration and higher BMI predicted
achievement of target glycemic control among subjects diagnosed or followed beyond age 12
years. It is reported in the literature (Mortensen et al., 1998, 2008; Cutfield et al., 2011) females
were less likely to achieve target glycemic control compared to males. Gender specific
differences in pubertal hormonal changes, higher risk of noncompliance, and higher prevalence
of eating disorders may be responsible for the difference. We suspect that the same may apply to
our study. Furthermore, we found that longer diabetes duration predicted achievement of the
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target glycemic control. While other studies have found the opposite (Rosilio et al., 1998,
Cutfiled et al., 2011), this association could be the result of improved understanding and
knowledge of diabetes with a longer duration of disease. Longer exposure to the specialized
diabetes program and more confident diabetes self management could contribute to the
improvement of the glycemic control.
Finally, we found that higher BMI was predictive of the achievement of glycemic control among
subjects over 12 years old. Other reports, including Dorchy and colleagues (1997), have also
demonstrated a positive relationship between glycemic control and BMI. We measured BMI at
diabetes diagnosis and we hypothesize BMI to be a marker of severity of diabetes at its onset.
Absolute lack of insulin often results in a catabolic state and significant weight loss. We suspect
that subjects who presented with less severe metabolic decompensation at diagnosis as indicated
by a higher BMI, may have different, and possibly easier to control T1D. It is important to note
that in our study, the BMI values were calculated using available weight and height
measurements. As noted in the previous chapters, those values had no associated units and it is
possible that a proportion of the calculations may be incorrect.

5.2 Study Strengths
This is the first study in Canada examining predictors of glycemic control in a large regional
T1D pediatric cohort being treated under ‘real world’ conditions. Data used in this study was
obtained using a clinical electronic database (Humabase) of pediatric diabetes patients in the
region. Virtually every diabetes patient in Southwestern Ontario is followed by the specialized
diabetes program at the Children’s Hospital in London and has data entered in the electronic
database used in this study. Our study included information on 996 T1D pediatric patients from a
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single center in a geographically defined region and it is the largest study of its kind in Canada.
Thus the results of this study are likely to be generalizable to other Canadian if not North
American centers.
Finally, our study provided a unique design with clinically-rich longitudinal cohort data used to
describe clinically relevant outcomes in children and adolescents with T1D in the Southwestern
Ontario region. Using the available database, we were able to create a large cohort of T1D
pediatric patients in Ontario and Canada. This cohort can be used for future studies including
linkage of data with provincial administrative health databases that capture information on major
outcomes (e.g. complications) in adulthood. This could provide future opportunities to determine
and eventually improve health policy outcomes of the regional pediatric diabetes model.
Furthermore, the subjects included in the study are all followed by the same specialized diabetes
program at Children’s Hospital in London and therefore can serve as an ongoing population
cohort for future studies.

5.3 Study Limitations
Our study had limitations. Subjects with newly diagnosed diabetes and those within the first year
of diagnosis were excluded. This was chosen to minimize selection bias in our study and to
ensure a more homogenous group of subjects. The application of exclusion criteria avoided
inclusion of patients who were in remission and therefore might have had better chance of
achieving the target glycemic control. Subjects who were lost to clinical follow up also had less
frequent clinical visits and were underrepresented in our study. Other authors (Kaufman, et al.,
1999, 2002; Urbach et al., 2005) have suggested that children with T1D who attend the
specialized clinics more frequently achieve better glycemic control, while Hannenberg and
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colleagues (2008) found the opposite, i.e. more frequent visits were associated with worse
glycemic control. It is possible that through underrepresentation of cases with infrequent visits
we introduced a selection bias which excluded subjects who differed with respect to other
variables of interest (for example income level). This could be the possible explanation for why
we did not find a significant effect of selected variables (income level) on glycemic control.
Selection bias through underrepresentation of cases with shorter diabetes duration is a further
limitation of our study design. It has been shown in literature that shorter duration of diabetes
was associated with improved gycemic control (Mortenson et al., 1998; Gerstel et al., 2007;
Petitti et al., 2009). We found the opposite; the longer duration of diabetes was significantly
associated with improved glycemic control. There are two general explanations for why we
demonstrated an opposite effect. One scenario is that this is a true association. A second scenario
is that this study failed to identify a true association. Subjects with shorter diabetes duration who
were excluded from the study were also younger and had they been included in the analysis a
different direction the association might have been demonstrated. We applied stratified sampling
(where we used three different age categories) to minimize the selection bias and improve
representation of all cases.
Another limitation of our study was the inability to control for known and unknown confounding
factors. This arose because of the observational study design and, related to that, inherent
deficiencies in the Humabase data. The choice of variables for inclusion in the study were based
on a literature review but were also modified according to unavoidable limitations specific to
Humabase. For example, frequency of self-monitoring of blood glucose was shown to strongly
predict improved level of glycemic control (Johannesen et al., 2008). While this information is

62

available in the office paper patient chart, it is not recorded in Humabase. Therefore, we did not
include this variable in our study. Similarly, no socio-economic variables (i.e. income or parental
education, etc) were recorded in the Humabase. But the permanent address with a postal code
was available. We used the postal code information to derive an average household income as
well as a distance from the treatment center in our study. Other important variables, such as
insulin regimen, dose, and hospitalizations for DKA and/or hypoglycemia were not recorded in
Humabase. There existed limited information on the use of an insulin pump and the percentage
of missing data was above 80% thus it precluded thier inclusion in the study. Lack of
information on treatment regimens such as insulin type, mode of delivery, and insulin dose could
have an important effect on glycemic control eventhough well conducted large studies in similar
populations found no association between insulin regimens and glycemic control (Morgensen et
al., 1998; Rosalio et al., 1998). Moreover, in our study all subjects were followed and managed
at the same specialized pediatric program making it likely that participants received the same
standard of care including standardized insulin treatment. However, because Humabase lacked
this information, the question remained unexplored in our study.
A proportion of subjects were excluded from analysis due to missing data. No imputation of
missing data was conducted. Analysis of the missing data in our study found excluded subjects to
be younger, have shorter diabetes duration, and lived further away from London. Exclusion of
the missing data may be one of the explanations why in our study there was no statistically
significant association of age and glycemic control or the positive association between diabetes
duration and achievement of glycemic control was found. Alternatively, age and duration of
diabetes could be closely related which explains why age did not enter the multivariable model.
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Finally, more subjects with missing data who were excluded from analysis lived further away
from London when compared with individuals included in the final analysis. There are
potentially important implications of this finding. One is that the distance from a specialized
diabetes program affected frequency of clinical visits. If the greater proportion of missing data
occurred in the group with less frequent visits, further conclusions have to be predicted on their
achievement of glycemic control, and potential unifying features of this excluded subset. It is our
speculation that a greater distance from a treatment center adversely affects glycemic control and
that exclusion of subjects with missing data might have contributed to the lack of such
relationship in each of our models. However, the percentage of missing data was limited and
therefore might not have significantly affected the results of our study overall.

5.4 Future Directions
This study is the first in a series of analyses that will utilize this large regional pediatric T1D
cohort to assess clinical practice questions. Other available clinical data in Humabase include
blood pressure, cholesterol profile, renal indices, and details of other autoimmune disorders can
be analyzed using a similar study design. To further characterize this cohort and enhance the
research potential, completion of the database including details of different treatments (insulin
type, dose and delivery, other medications) should be completed. Establishment of this cohort
can significantly improve knowledge and allow for extensive research opportunities in the area
of pediatric diabetes care. Future studies involving linkage with provincial administrative
databases are planned to determine important outcomes (rate of diabetes-related hospitalizations,
micro and macrovascular disease complications, utilization of health care resources, etc) in this
cohort. Our study is an important step in establishing the utility of the regional clinical electronic
database in diabetes research.
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5.5 Conclusions
T1D is one of the most common chronic conditions in children and adolescents. The incidence of
T1D in children is increasing in Canada and around the globe. If the current trends continue, the
incidence of T1D will double in 20 years (Daneman, 2009). Improved metabolic control reduces
the onset and progression of diabetes-related complications and the current clinical practice
guidelines recommend aggressive attempts to achieve target glycemic control in children and
adolescents with T1D (CDA Executive Committee , 2008). However, good glycemic control is
difficult to achieve under ‘real world’ conditions. Therefore, improving the understanding of
factors associated with improved glycemic control in real-life, using effectiveness conditions is
essential.
Overall, we found a suboptimal level of glycemic control in the regional T1D pediatric cohort in
Southwestern Ontario. However, the average A1C level of the entire cohort was comparable with
the other pediatric diabetes programs in Canada (Manitoba). Our study has shown that many of
the same variables that were associated with glycemic control in the literature were relevant in
our population as well. Furthermore, the findings of our study showed that factors associated
with improved glycemic control were age-specific. Our study suggests that proximity to a
treatment center may be important for youngest patients and their families while the adolescent
females with relatively short duration of disease could be the specific group to target for
improved metabolic control. The limitations of the non-experimental design of the study prevent
firm conclusions from being drawn. However, diabetes care team members need to be aware of
factors associated with worse glycemic control so that targeted support and intensification of
resources may be considered for the high risk patient groups. The results of this study should
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assist in identifying strengths and potential areas of expansion for the regional pediatric diabetes
program.
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Appendix A - Utility of clinical database (HUMABASE) in the pediatric diabetes research:
Validation Study
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1.

Introduction

Humabase is an electronic clinical pediatric diabetes database. In 1987, Children’s Hospital at
London Health Sciences Center (LHSC) implemented Humabase to facilitate the clinical care
and to create a comprehensive registry of pediatric diabetes patients in Southwestern Ontario.
Since its implementation the program has maintained computerized clinical records of all
pediatric diabetes patients seen at the CH-LSHC. As of 2012, it has tracked over 1500 pediatric
diabetes patients. Ninety eight percent of the patients have type 1 diabetes (T1D). Virtually all
newly diagnosed T1D patients in Southwestern Ontario are seen by one of the endocrinologists
at the tertiary diabetes care program at the CH-LHSC and their data entered into Humabase.
Those patients either continue to be followed at the Children’s Hospital or the clinical outreach
programs in Sarnia, Chattam and Stratford. Data collected during outreach visits are entered in
Humabase as well.
Thus, Humabase is an electronic registry that contains comprehensive clinical information about
all pediatric T1D patients diagnosed in Southwestern Ontario since 1987. It therefore has
significant potential to address research questions in pediatric T1D patients who have been
managed under ‘real world’ conditions. However, a prerequisite to such research is to assess the
accuracy of the Humabase relative to an existing reference standard of hospital and offica paper
charts (i.e. to validate Humabse).
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1.1.

Objectives

The objective of this validation study is to determine the accuracy of data in the clinical
electronic database (Humabase).
2. Methods and Materials
2.1. Software Description
Humabase+ is MS-DOS based software created by MedicaLogic and was donated free of charge
to the LHSC Children’s Hospital diabetes program by Eli Lilly pharmaceutical company in 1987.
Humabase+ software program was designed specifically for practice devoted to diabetes care. It
was intended to provide computerized clinical records, patient education (printed patient
handouts), research (searchable dBase III+) and practice management (summarized practice
reports). The application therefore has multiple functions, but is only in limited use at the CHLHSC. At present, Humabase is only used to record clinical encounter data.
The Humabase+ software is not produced and company no longer support the product.
Humabase was last updated was in 2000 to ensure no Y2K problems affect the database.
Transition to the new millennium was successful but since then there have been no software
updates or technical support available. Thus, software is still in the use at the CH- LHSC.
Initially it was installed and used on a desktop only, but was then moved to a hospital server and
password protected.
2.2. Data Entry
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2.2.1. Personnel
Data entry is done exclusively by the administrative support staff using MS-DOS screen (“black
screen”). No physician enters any clinical or other data. There has been no formal training for the
data entry. There is a User’s manual provided by Eli Lilly (published 1990) but this manual was
not used by the data entry personal. Since 1987, there has been one data entry person who
continues to use Humabase regularly. This person is no longer working on data entry. There have
also been a couple of data entry people who entered data short term. Currently, there are two data
entry persons using the software. They have not standardized their data entry practices and the
same data entry person has changed her practices over the years.
2.2.2. Modes of Operation
Since Humabase data entry is done using MS DOS screen, a keyboard has to be used to navigate
through the program and enter data. Humabase has three modes of operation: Menu Selection,
Data Entry, and Text Typing. Humabase has a capability of displaying variety of screens that
often contain several “pop up” windows. All the screens have consistent features. The title
always appears in the top center and the bottom line of the screen contains an explanation of
what keys to press. There are only two screens used within the Menu Selection which are Patient
Registration and Chart module. Neither of these screens have mandatory fields. Most data fields
are a character variable type (except for the two date fields: date of birth and visit date), which
means that any text can be entered and saved. There are no data format checks and limitations if
numeric values such as test results are entered. For example, if a numeric test value is entered,
the data entry person is not prevented to enter any associated description (such as name of the
laboratory where the test was performed).
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Approximately 5 years ago the administrative staff deleted a small number of records that were
inactive. These records have not been permanently deleted and were retrieved from the backup
copy for the purposes of the validation study and also the main thesis.

2.2.3. Available Variables
Humabase contains clinical records of 1,490 patients and 24,906 clinical encounters entered
between October 1992 and June 2009. Humabase has been in use since 1987, however only the
data stored on a hospital server (1992 and onward) is available. There are only two program
modules that are used for data entry: Registration and Flowsheet. Every patient clinical visit is
entered as a separate encounter. Each encounter has a specific date that is formatted
(DD/MM/YYYY) and entered under the title note date. Patients may have only one encounter or
up to 40 encounters that span over 15 years.
The following data are entered to create a new registration:
1.

Name (Last, First Middle).

2.

Address (multiple lines) that includes separate fields for City, State and Zip (postal code
number in Canada).

3.

Birth Date (MM/DD/YYYY),

4.

Sex (M/F),

5.

Marital status (Single or other)
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6.

Care provider code (character field),

7.

Diagnosis (character filed)

8.

Initial date of diagnosis (character filed),

9.

Referral physician name (character filed)

Each new patient is assigned unique account number automatically by the program. With each
subsequent visit, the account number remains the same and the above data is edited by the data
entry person.
A flowsheet is used to enter clinical data. It is a combination of limited historic, physical exam
and laboratory data. Since the system allows a print maximum of 40 data points per page, the
number of clinical information points entered was limited to 40. The flowsheet lists those values
ordered by the visit dates. At present it is kept in the electronic record but viewed by physician
only in the hard copy form (Appendix D). Following are data entered into flowsheet : Age in
years, Age in months, Weight, Weight Percentile, Height, Height Percentile, Blood
Pressure(systolic and diastolic), Pulse, Random blood glucose value, Blood glucose value from
the glucometer, Glycated Hemoglobin (GHB), TSH, Registered Nurse visit, HDL, LDL, Total
Cholesterol, Triglyceride, Registered Dietitian visit, Urine Protein, Urine Glucose, Urine
Ketones, Urine Blood, Urine Leukocytes, Albumin to Creatinine ratio, 24 hour Urinary
Creatinine Clearance (CrCl), 24 hour Urinary Microalbumin, 24 hour Urinary Protein, Pump
Information, Free T4 (thyroxine), Total T3, Antithyroid and other Antibodies (ATMA, ATA),
Tanner pubertal stage, Age of Menarche, Last menstrual Period, Ophthalmology involvement,
School name, grade, and diabetes camp attendance. All fields are character values.
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2.3. Data Entry and Clinical Workflow Description
An administrative data entry person enters patient demographic information at the initial visit.
This usually occurs at the time of diagnosis. Data is entered using the Children’s hospital
registration system as a reference. At each subsequent visit, these data can be edited and new
clinical information can be entered. Therefore each clinical visit is recorded in the Humabase.
There are no mandatory entry clinical fields and as little as 2 to a maximum of 40 clinical
variables may be entered at each visit. Clinical data is entered using the patient chart as the
reference standard. Data entry usually follows a 2-step process. Prior to the visit any available
laboratory results are entered (TSH, urinary test results, etc). Subsequent to the visit (and usually
a week prior to the next visit), the pediatric diabetes clinical flowsheet will be used to
retrospectively enter limited physical exam data and GHB value (which is done during the visit
by point of care testing).
2.3.1. Pediatric Diabetes Clinical Flowsheet (PDCF)
The diabetes clinical flowsheet (Appendix E) is a paper form that is completed during the
actually visit by members of the multidisciplinary team (physician, registered nurse, registered
dietitian and social worker) but also by the patient/family members. Patients or their caregivers
enter their age, blood glucose values from their log book and insulin regimen (type and quantity
of insulin). Nursing staff enter height, weight, systolic and diastolic blood pressure taken at the
visit, as well as the result of point of care GHB testing. The rest of the information is entered
mostly by the diabetes educator or physician and is descriptive in nature (medical assessment and
plan). Only a portion of data collected and recorded in the paper chart is entered in Humabase.
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2.4 Methods: Validation
2.4.1 Sample Size
A computer generated random sample of 1% of all recorded clinical encounters was selected
(n=250) for the validation. Figure 1 shows how the sample was obtained.
Figure 1: Sample Derivation

Clinical Encounters
Screened (random)
N=500

Paper Charts not
accessible
N = 179 (35.8%)

Unable to retrieve (MD
moved, retired or stored
records off site)

Encounters excluded
Not a clinical encounter
N = 71 (14.2%)

Final sample
N=250
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2.4.2. Validation Coding
The following codes were used to assess the accuracy of the Humabase:
1.

Complete Match (CM) – the reference standard value and Humabase value

matched.
2.

Partial Match (PM) - the reference standard value and Humabase value differ in

form but the value and meaning of the information was preserved.
3.

No match (NM) – values do not match or are not recorded making validation

impossible. Values may be missing from the Humabase or the paper chart (refernce
standard).
If the values were not recorded in either Humabase or the paper chart, this was interpreted as
Data Not Collected or Test Not Performed. In this case, the encounter was coded as a complete
match (CM).
2.4.3. Reference Standard
To determine the accuracy of electronic data, paper chart (Pediatric Diabetes Clinical Flowsheet)
is used as a gold standard as well as printed laboratory reports filed in the paper chart
(Appendix E).
2.4.2. Variables Chosen for Validation
Eighteen variables were validated for accuracy:
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Visit date, Systolic and diastolic blood pressure, weight, weight percentile, height, height
percentile, age (years and months), GHB, TSH, Microalbumin to creatinine Ratio, 24 hour
creatinine clearance and urinary protein, Tanner pubertal stage, pump information,
ophthalmology involvement, and visits with registered nurse and dietitian.
A many other variables were potentially available for comparison between Humabase and the
paper charts but were not included as part of the validation procedure. For example, some of the
clinical values have changed in clinical relevance over time (e.g. urinary ketones). In other cases,
a representative value for a group of test was chosen to be validated. Thus, when urinalysis
values were assessed validated, only 2 out of 5 tests were validated (urinary albumin and 24
CrCl). Other variables were deemed unimportant in terms of determining the database (e.g.,
spelling of school names).
3. Results
Eighteen variables were validated (Table 1). Ten variables demonstrated very high accuracy with
complete match reported at least 95% of the time. The highest accuracy was demonstrated for
GHB, urinary indices, blood pressure, weight, height, age, Tanner stage, visit date and record of
the visit with the diabetes nurse educator. Of the remaining 8 variables, the rate of complete
matching ranged from 55.6% (ophthalmology visits) to 88.8%.
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Table 1: Frequency of Agreement between Humabase and Refernce Standard
Variable Name

Complete Match (%)

Partial Match (%)

No match (%)

GHB

238 (95.2%)

2 (0.8%)

10 (4.0%)

TSH

222 (88.8%)

26 (10.4%)

2 (0.8%)

Microalbumin to
Creatinine Ratio

245 (98%)

0 (0 %)

5 (2.0%)

24 hour Creatinine

250 (100%)

0

0

24 hour Urinary
Protein

250 (100%)

0

0

Blood pressure

248 (99.2%)

0

2 (0.8%)

Weight

246 (98.4%)

0

4 (1.6%)

Weight percentile

209 (83.6%)

19 (7.6%)

22 (8.8%)

Height

247 (99.8%)

0

3 (1.2%)

Height percentile

209 (83.6%)

19 (7.6%)

22 (8.8%)

Age (year)

247 (99.8%)

2 (0.8%)

1 (0.4%)

Age (months)

245

3

2

Registered Nurse*

185 (93.9%)

1 (0.5%)

11 (55.8%)

Registered Dietitian

214 (85.6%)

2 (0.8%)

34 (13.6%)

Pump information*

188 (87.9%)

0

26 (12.1%)

Tanner stage

242 (96.7%)

0

8 (3.2%)

Ophthalmology visit

139 (55.6%)

1 (0.4%)

110 (44%)

Visit Date

240 (96%)

0

10 (4%)

Clearance

*Reference standard (PDCF) used prior to 1998 had no provision for entry of data.
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3.1 Additional Findings
In this random sample of 250 encounters, specific diabetes diagnosis was recorded for 248 visits
(99.2%), while missing in 2 encounters (0.8%). Of those, 240 encounters had T1D (96%)
recorded as diabetes type, 5 were Type 2 Diabetes (2%) and 3 (1.2%) were for other clinical
problems (Cystic fibrosis related diabetes, IGT, and Bardinelli syndrome).
In the validation sample, only 2 visits (0.8%) were duplicated and the same clinical encounter
data.
4. Discussion
In this validation study, we demonstrated high level of agreement between Humabase and
reference standard that ranges from 55.6% to 100 % and overall Humabase accuracy of over
90%. Eventhough the accuracy is high, there were important limitations. First, we assessed the
accuracy of the Humabase against the paper charts as a reference standard. It is possible that data
in the paper chart was inaccurate. Since the data in the electronic database was entered by the
administrative staff from the chart, what we validated was the accuracy of data transcription.
Second, we have validated only the Humabase designated data format. For example, weight and
height were entered with no measurement units attached. While the accuracy of the value itself is
very good (>98%), the lack of the associated unit (meters of inches) could make these data
clinically less applicable.
Finally, we found that 19.4% of specific encounter data were missing in the Humabase. The
validation study was not designed to assess the completeness, rather only the accuracy of data
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that were entered. In a research setting, this rate of missing results could affect research the
utility of Humabase, though the impact would depend upon which data were missing in the
context of the specific research question(s) being asked.
The results of this validation study support the use of the Humabase data in the main thesis and
the validity of the thesis findings.
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Appendix B - Western University Health Sciences Research Ethics Board Approval.
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Appendix C - Regression Analyses: Results of Forward Selection Procedure.

Model 1
(Age < 6 years)

p value

Model 2
(Age 6 – 12
years)

p value

Model 3
(Age > 12 years)

p value

1.00
0.45 (0.27-0.74)

0.002

Variables
Gender
Male
Female
Age (years)

Distance from London
< 50 km
>50 km

-

-

-

-

-

-

-

-

-

Diabetes duration
(years)

-

-

1.12 (1.05-1.20)

0.001

Body Mass Index
(kg/m2)

-

-

1.07 (1.01-1.13)

0.021

Previous Control
No
Yes

N/A

Household Income
< $57,000
>$57,000

1.00
0.35 (0.16-0.74)

-

0.011

1.00
1.25 (0.92-1.71)

0.158

1.00
1.54 (0.98-2.43)

0.062
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Appendix D - Humabase Diabetes Clinical Flowsheet.
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Appendix E - Pediatric Diabetes Clinical Flowsheet.
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